Engineering blood stem cells for autologous transplants for lysosomal diseases: Correction of mucopolysaccharidosis type I using genome-edited hematopoietic stem and progenitor cells

2018 ◽  
Vol 123 (2) ◽  
pp. S54-S55
Author(s):  
Natalia Gomez-Ospina ◽  
Samantha G. Scharenberg ◽  
Sruthi Mantri ◽  
Carmencita Nicolas ◽  
Rasmus Otkjaer Bak O. Bak ◽  
...  
2018 ◽  
Author(s):  
Natalia Gomez-Ospina ◽  
Sam Glynne Scharenberg ◽  
Nathalie Mostrel ◽  
Rasmus O. Bak ◽  
Sruthi Mantri ◽  
...  

SummaryLysosomal enzyme deficiencies comprise a large group of genetic disorders that generally lack effective treatments. A potential treatment approach is to engineer the patient’s own hematopoietic system to express high levels of the deficient enzyme, thereby correcting the biochemical defect and halting disease progression. Here, we present an efficient ex vivo genome editing approach using CRISPR/Cas9 that targets the lysosomal enzyme iduronidase to the CCR5 safe harbor locus in human CD34+ hematopoietic stem and progenitor cells. The modified cells secrete supra-endogenous enzyme levels, maintain long-term repopulation and multi-lineage differentiation potential, and can correct biochemical and phenotypic abnormalities in an immunocompromised mouse model of Mucopolysaccharidosis type I. Our studies provide support for the development of human, genome-edited CD34+ hematopoietic stem and progenitor cells for the treatment of a multi-systemic lysosomal storage disorder. Our safe harbor approach constitutes a flexible platform for the expression of lysosomal enzymes, exemplifying a potential new paradigm for the treatment of these diseases.


2019 ◽  
Vol 10 (1) ◽  
Author(s):  
Natalia Gomez-Ospina ◽  
Samantha G. Scharenberg ◽  
Nathalie Mostrel ◽  
Rasmus O. Bak ◽  
Sruthi Mantri ◽  
...  

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4336-4336
Author(s):  
Leo D. Wang ◽  
Phi Nguyen ◽  
Scott B Ficarro ◽  
John Hutchinson ◽  
Oliver Hofmann ◽  
...  

Abstract Cellular functions are largely effected by proteins, but protein-level analysis of hematopoietic stem and progenitor cell (HSPC) functions has historically been challenged by the difficulty of performing comprehensive and robust proteomic studies of rare cell populations. To confront this challenge, we developed a novel nanoscale multidimensional mass spectrometry-based phosphoproteomic platform that allows, for the first time, comprehensive and unbiased analysis of the activated protein circuits in blood stem cells, as assessed by protein phosphorylation status. We used this platform to interrogate the proteomic features responsible for the growth and maintenance of hematopoietic progenitors. Our analysis pipeline is capable of returning 12,000 unique phosphopeptide sequences (corresponding to several thousand proteins) from an input of 400,000 FACS-sorted primary mouse HSPCs. Among these phosphorylated proteins, the novel Rac-GAP Arhgap25 emerged as an important regulator of mobilization in HSPCs. Arhgap25 is phosphorylated upon treatment of HSPCs with a standard cyclophosphamide-GCSF mobilization protocol. Germline deletion of Arhgap25 in mice impairs HSPC egress from the bone marrow, both at rest and after mobilizing stimuli. These findings validate the use of this platform in the discovery of new therapeutic targets in hematopoiesis, and present a clear pathway for identifying novel targets in other rare subsets of human progenitor cells, including leukemia stem cells. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document